retatrutide clinical trial retatrutide drug Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation This weight-loss drug hasn't been

Tirzepatide, a dual glucagon-like peptide-1 (GIP) and GLP-1RAs, administered once weekly at a 15 mg dose, resulted in an average weight loss of 20.9% over 72 weeks (Jastreboff et al., 2022), driven by its synergistic effects on appetite regulation, energy intake reduction, and fat mass decrease (Heise et al., 2023)

These are most prominent when starting the medication and during dose escalation, and typically improve as the body adjusts

The consistency of results deserves mention

Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances

This article explores what happens when you stop Ozempic suddenly, the associated risks, and how to discontinue treatment safely under medical supervision